Application of 18F-Fluorodeoxyglucose and PET in Evaluation of the Diabetic Foot

PET Clinics

Volumn 1, Issue 2, 2006, Pages 123-130

  Hochhold, John ^a,b   Yang, Hua ^a,b   Zhuang, Hongming ^a,b,c   Alavi, Abass ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34250852446     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2006.03.001     Document Type: Review

References (70)

1. Boulton A.J., and Vileikyte L. The diabetic foot: the scope of the problem. J Fam Pract 49 Suppl (2000) S3-S8
2. Gordois A., Scuffham P., Shearer A., et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care 26 (2003) 1790-1795
3. Levine S.E., Neagle C.E., Esterhai J.L., et al. Magnetic resonance imaging for the diagnosis of osteomyelitis in the diabetic patient with a foot ulcer. Foot Ankle Int 15 (1994) 151-156
4. Lipsky B.A. A current approach to diabetic foot infections. Curr Infect Dis Rep 1 (1999) 253-260
5. Lipsky B.A. A report from the International Consensus on diagnosing and treating the infected diabetic foot. Diabetes Metab Res Rev 20 Suppl 1 (2004) S68-S77
6. Schinabeck M.K., and Johnson J.L. Osteomyelitis in diabetic foot ulcers. Prompt diagnosis can avert amputation. Postgrad Med 118 (2005) 11-15
7. Williams D.T., Hilton J.R., and Harding K.G. Diagnosing foot infection in diabetes. Clin Infect Dis 39 Suppl 2 (2004) S83-S86
8. Armstrong D.G., Lavery L.A., Sariaya M., et al. Leukocytosis is a poor indicator of acute osteomyelitis of the foot in diabetes mellitus. J Foot Ankle Surg 35 (1996) 280-283
9. Eneroth M., Apelqvist J., and Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int 18 (1997) 716-722
10. Berendt A.R., and Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. Curr Diab Rep 4 (2004) 424-429
11. Newman L.G., Waller J., Palestro C.J., et al. Leukocyte scanning with 111In is superior to magnetic resonance imaging in diagnosis of clinically unsuspected osteomyelitis in diabetic foot ulcers. Diabetes Care 15 (1992) 1527-1530
12. Nardone D.A. Probing to bone in infected pedal ulcers. JAMA 274 (1995) 869-870
13. Sommer T.C., and Lee T.H. Charcot foot: the diagnostic dilemma. Am Fam Physician 64 (2001) 1591-1598
14. Bonakdar-pour A., and Gaines V.D. The radiology of osteomyelitis. Orthop Clin North Am 14 (1983) 21-37
15. Schweitzer M.E., and Morrison W.B. MR imaging of the diabetic foot. Radiol Clin North Am 42 (2004) 61-71
16. Sella E.J., and Grosser D.M. Imaging modalities of the diabetic foot. Clin Podiatr Med Surg 20 (2003) 729-740
17. Zhuang H., Sam J.W., Chacko T.K., et al. Rapid normalization of osseous FDG uptake following traumatic or surgical fractures. Eur J Nucl Med Mol Imaging 30 (2003) 1096-1103
18. Johnson J.E., Kennedy E.J., Shereff M.J., et al. Prospective study of bone, indium-111-labeled white blood cell, and gallium-67 scanning for the evaluation of osteomyelitis in the diabetic foot. Foot Ankle Int 17 (1996) 10-16
19. Yuh W.T., Corson J.D., Baraniewski H.M., et al. Osteomyelitis of the foot in diabetic patients: evaluation with plain film, 99mTc-MDP bone scintigraphy, and MR imaging. AJR Am J Roentgenol 152 (1989) 795-800
20. Keenan A.M., Tindel N.L., and Alavi A. Diagnosis of pedal osteomyelitis in diabetic patients using current scintigraphic techniques. Arch Intern Med 149 (1989) 2262-2266
21. Nelson H.T., and Taylor A. Bone scanning in the diagnosis of acute osteomyelitis. Eur J Nucl Med 5 (1980) 267-269
22. Larcos G., Brown M.L., and Sutton R.T. Diagnosis of osteomyelitis of the foot in diabetic patients: value of 111In-leukocyte scintigraphy. AJR Am J Roentgenol 157 (1991) 527-531
23. Seabold J.E., Flickinger F.W., Kao S.C., et al. Indium-111-leukocyte/technetium-99m-MDP bone and magnetic resonance imaging: difficulty of diagnosing osteomyelitis in patients with neuropathic osteoarthropathy. J Nucl Med 31 (1990) 549-556
24. Alazraki N., Dries D., Datz F., et al. Value of a 24-hour image (four-phase bone scan) in assessing osteomyelitis in patients with peripheral vascular disease. J Nucl Med 26 (1985) 711-717
25. Israel O., Gips S., Jerushalmi J., et al. Osteomyelitis and soft-tissue infection: differential diagnosis with 24 hour/4 hour ratio of Tc-99m MDP uptake. Radiology 163 (1987) 725-726
26. Rosenthall L. Radionuclide investigation of osteomyelitis. Curr Opin Radiol 4 (1992) 62-69
27. Blume P.A., Dey H.M., Daley L.J., et al. Diagnosis of pedal osteomyelitis with Tc-99m HMPAO labeled leukocytes. J Foot Ankle Surg 36 (1997) 120-126 [discussion: 160]
28. Palestro C.J., Mehta H.H., Patel M., et al. Marrow versus infection in the Charcot joint: indium-111 leukocyte and technetium-99m sulfur colloid scintigraphy. J Nucl Med 39 (1998) 346-350
29. King A.D., Peters A.M., Stuttle A.W., et al. Imaging of bone infection with labelled white blood cells: role of contemporaneous bone marrow imaging. Eur J Nucl Med 17 (1990) 148-151
30. Craig J.G., Amin M.B., Wu K., et al. Osteomyelitis of the diabetic foot: MR imaging-pathologic correlation. Radiology 203 (1997) 849-855
31. Erdman W.A., Tamburro F., Jayson H.T., et al. Osteomyelitis: characteristics and pitfalls of diagnosis with MR imaging. Radiology 180 (1991) 533-539
32. Lipman B.T., Collier B.D., Carrera G.F., et al. Detection of osteomyelitis in the neuropathic foot: nuclear medicine, MRI and conventional radiography. Clin Nucl Med 23 (1998) 77-82
33. Morrison W.B., Schweitzer M.E., Wapner K.L., et al. Osteomyelitis in feet of diabetics: clinical accuracy, surgical utility, and cost-effectiveness of MR imaging. Radiology 196 (1995) 557-564
34. Marcus C.D., Ladam-Marcus V.J., Leone J., et al. MR imaging of osteomyelitis and neuropathic osteoarthropathy in the feet of diabetics. Radiographics 16 (1996) 1337-1348
35. Morrison W.B., and Ledermann H.P. Work-up of the diabetic foot. Radiol Clin North Am 40 (2002) 1171-1192
36. Vesco L., Boulahdour H., Hamissa S., et al. The value of combined radionuclide and magnetic resonance imaging in the diagnosis and conservative management of minimal or localized osteomyelitis of the foot in diabetic patients. Metabolism 48 (1999) 922-927
37. Morrison W.B., Schweitzer M.E., Batte W.G., et al. Osteomyelitis of the foot: relative importance of primary and secondary MR imaging signs. Radiology 207 (1998) 625-632
38. Chacko T.K., Zhuang H., Nakhoda K.Z., et al. Applications of fluorodeoxyglucose positron emission tomography in the diagnosis of infection. Nucl Med Commun 24 (2003) 615-624
39. Ledermann H.P., Morrison W.B., and Schweitzer M.E. MR image analysis of pedal osteomyelitis: distribution, patterns of spread, and frequency of associated ulceration and septic arthritis. Radiology 223 (2002) 747-755
40. Zhuang H., Yu J.Q., and Alavi A. Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am 43 (2005) 121-134
41. Stumpe K.D., Zanetti M., Weishaupt D., et al. FDG positron emission tomography for differentiation of degenerative and infectious endplate abnormalities in the lumbar spine detected on MR imaging. AJR Am J Roentgenol 179 (2002) 1151-1157
42. Temmerman O.P., Heyligers I.C., Hoekstra O.S., et al. Detection of osteomyelitis using FDG and positron emission tomography. J Arthroplasty 16 (2001) 243-246
43. Zhuang H., Duarte P.S., Pourdehnad M., et al. The promising role of 18F-FDG PET in detecting infected lower limb prosthesis implants. J Nucl Med 42 (2001) 44-48
44. Stumpe K.D., Dazzi H., Schaffner A., et al. Infection imaging using whole-body FDG-PET. Eur J Nucl Med 27 (2000) 822-832
45. Ichiya Y., Kuwabara Y., Sasaki M., et al. A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma. Ann Nucl Med 10 (1996) 193-200
46. Stumpe K.D., Notzli H.P., Zanetti M., et al. FDG PET for differentiation of infection and aseptic loosening in total hip replacements: comparison with conventional radiography and three-phase bone scintigraphy. Radiology 231 (2004) 333-341
47. Ichiya Y., Kuwabara Y., Sasaki M., et al. FDG-PET in infectious lesions: the detection and assessment of lesion activity. Ann Nucl Med 10 (1996) 185-191
48. Kalicke T., Schmitz A., Risse J.H., et al. Fluorine-18 fluorodeoxyglucose PET in infectious bone diseases: results of histologically confirmed cases. Eur J Nucl Med 27 (2000) 524-528
49. Zhuang H., Duarte P.S., Pourdehand M., et al. Exclusion of chronic osteomyelitis with F-18 fluorodeoxyglucose positron emission tomographic imaging. Clin Nucl Med 25 (2000) 281-284
50. Zhuang H., and Alavi A. 18-Fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 32 (2002) 47-59
51. Sahlmann C.O., Siefker U., Lehmann K., et al. Dual time point 2-[18F]fluoro-2′-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis. Nucl Med Commun 25 (2004) 819-823
52. Keidar Z., Militianu D., Melamed E., et al. The diabetic foot: initial experience with 18F-FDG PET/CT. J Nucl Med 46 (2005) 444-449
53. Hopfner S., Krolak C., Kessler S., et al. Preoperative imaging of Charcot neuroarthropathy in diabetic patients: comparison of ring PET, hybrid PET, and magnetic resonance imaging. Foot Ankle Int 25 (2004) 890-895
54. Cheung M.H.J., Reddy S., Newberg A., et al. Diagnostic accuracy of FDG-PET imaging in detecting osteomyelitis of the diabetic foot. J Nucl Med 46 (2005) 134-135
55. Zhuang H.M., Cortes-Blanco A., Pourdehnad M., et al. Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders?. Nucl Med Commun 22 (2001) 1123-1128
56. Koort J.K., Makinen T.J., Knuuti J., et al. Comparative 18F-FDG PET of experimental Staphylococcus aureus osteomyelitis and normal bone healing. J Nucl Med 45 (2004) 1406-1411
57. Alnafisi N., Yun M., and Alavi A. F-18 FDG positron emission tomography to differentiate diabetic osteoarthropathy from septic arthritis. Clin Nucl Med 26 (2001) 638-639
58. Makinen T.J., Lankinen P., Poyhonen T., et al. Comparison of (18)F-FDG and (68)Ga PET imaging in the assessment of experimental osteomyelitis due to Staphylococcus aureus. Eur J Nucl Med Mol Imaging 32 (2005) 1259-1268
59. Brunner M., Langer O., Dobrozemsky G., et al. [18F]Ciprofloxacin, a new positron emission tomography tracer for noninvasive assessment of the tissue distribution and pharmacokinetics of ciprofloxacin in humans. Antimicrob Agents Chemother 48 (2004) 3850-3857
60. Langer O., Brunner M., Zeitlinger M., et al. In vitro and in vivo evaluation of [18F]ciprofloxacin for the imaging of bacterial infections with PET. Eur J Nucl Med Mol Imaging 32 (2005) 143-150
61. Pellegrino D., Bonab A.A., Dragotakes S.C., et al. Inflammation and infection: imaging properties of 18F-FDG-labeled white blood cells versus 18F-FDG. J Nucl Med 46 (2005) 1522-1530
62. Makinen T.J., Veiranto M., Knuuti J., et al. Efficacy of bioabsorbable antibiotic containing bone screw in the prevention of biomaterial-related infection due to Staphylococcus aureus. Bone 36 (2005) 292-299
63. Koch C.J., Hahn S.M., Rockwell Jr. K., et al. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles. Cancer Chemother Pharmacol 48 (2001) 177-187
64. Gronroos T., Eskola O., Lehtio K., et al. Pharmacokinetics of [18F]FETNIM: a potential marker for PET. J Nucl Med 42 (2001) 1397-1404
65. Evans S.M., Kachur A.V., Shiue C.Y., et al. Noninvasive detection of tumor hypoxia using the 2-nitroimidazole [18F]EF1. J Nucl Med 41 (2000) 327-336
66. Evans S.M., Hahn S.M., Magarelli D.P., et al. Hypoxia in human intraperitoneal and extremity sarcomas. Int J Radiat Oncol Biol Phys 49 (2001) 587-596
67. Evans S.M., Hahn S., Pook D.R., et al. Detection of hypoxia in human squamous cell carcinoma by EF5 binding. Cancer Res 60 (2000) 2018-2024
68. Dolbier Jr. W.R., Li A.R., Koch C.J., et al. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. Appl Radiat Isot 54 (2001) 73-80
69. Barthel H., Wilson H., Collingridge D.R., et al. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 90 (2004) 2232-2242
70. Ziemer L.S., Evans S.M., Kachur A.V., et al. Noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18F-EF5. Eur J Nucl Med Mol Imaging 30 (2003) 259-266